Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
BCTX | US
-0.04
-1.21%
Healthcare
Biotechnology
30/04/2024
02/06/2026
3.27
3.26
3.41
3.20
BriaCell Therapeutics Corp. an immuno-oncology-focused biotechnology company engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver Canada.
View LessNegative Momentum (Declining Price)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
94.5%1 month
118.0%3 months
88.1%6 months
138.2%-
-
17.03
-
-
-1.38
-
-
-35.25M
117.35M
117.35M
-
-
-
-
-206.01
0.04
1.56
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.80
Range1M
1.36
Range3M
1.67
Rel. volume
0.72
Price X volume
687.49K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| InflaRx N.V | IFRX | Biotechnology | 2.17 | 127.78M | -4.82% | n/a | 0.00% |
| Immuneering Corporation Class A Common Stock | IMRX | Biotechnology | 4.28 | 126.92M | -4.78% | n/a | 6.50% |
| Dermira Inc | DERM | Biotechnology | 6.02 | 124.78M | -1.15% | 47.08 | 201.92% |
| BLACK DIAMOND THERAPEUTICS INC. | BDTX | Biotechnology | 2.18 | 123.18M | -3.54% | n/a | 21.42% |
| Anthem Inc. CORP UNIT 050118 | ANTX | Biotechnology | 4.07 | 121.46M | -3.33% | n/a | 0.00% |
| Elicio Therapeutics Inc. | ELTX | Biotechnology | 11.49 | 120.29M | -5.20% | 5.18 | -388.56% |
| ProQR Therapeutics N.V | PRQR | Biotechnology | 1.47 | 120.07M | 3.52% | n/a | 53.73% |
| Connect Biopharma Holdings Limited American Depositary Shares | CNTB | Biotechnology | 2.15 | 118.80M | -8.12% | n/a | 0.29% |
| Canopy Growth Corporation | CGC | Drug Manufacturers-Specialty & Generic | 1.06 | 117.48M | -1.85% | n/a | 117.00% |
| Seer Inc. | SEER | Biotechnology | 1.87 | 114.87M | -0.53% | n/a | 7.43% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 40.57 | 116.51M | -0.44% | 5.16 | 19.82% |
| Virco Mfg. Corporation | VIRC | Building Products & Equipment | 6.01 | 97.90M | 0.84% | 9.09 | 39.79% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 7.09 | 67.49M | 2.75% | n/a | 19.98% |
| ILAG | ILAG | Building Products & Equipment | 3.6016 | 65.04M | -4.21% | n/a | 5.48% |
| Saga Communications Inc | SGA | Broadcasting - Radio | 9.37 | 58.67M | -0.64% | 14.48 | 7.10% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 19.59 | 29.83M | 25.34% | n/a | 204.46% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 1.11 | 16.22M | -2.63% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.4275 | 8.26M | -0.47% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.71 | 4.37M | 1.18% | n/a | 17.32% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0063 | 580.95K | 12.50% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.38 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 17.03 | 15.55 | Par |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 88.06 | - | Riskier |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 117.35M | - | Emerging |